



March 23, 2020

ACADIA BUSINESS UPDATE REGARDING COVID-19

As the COVID-19 pandemic evolves globally, ACADIA has made it a priority to protect the health and safety of our employees, support patients who rely on our medicines and services, and do our part to minimize the spread of the novel coronavirus. ACADIA has taken several steps in the interest of public health:

We are protecting the wellbeing of our employees and communities.

Our San Diego, California and Princeton, New Jersey office locations, as well as our field-based commercial and medical employees, are working from home to reduce the potential risk of exposure and transmission of the virus. All international and domestic business travel is on hold. All employees are utilizing virtual meeting technology to conduct business whenever possible.

We are providing uninterrupted supply of NUPLAZID® (pimavanserin) to patients.

We are monitoring our supply chain closely and do not anticipate disruptions in our ability to deliver NUPLAZID® to patients. If you have questions about your prescription, we recommend you consult with your doctor first. If you have additional questions, you can reach ACADIA by phone in the U.S. at 1-844-422-2342 or by email medicalinformation@acadia-pharm.com.

We are advancing clinical research in accordance with regulatory guidance and local policies.

The health and safety of clinical trial participants and study partners is paramount. For our ongoing studies, we are following guidance from regulators and local policies to best maintain patient safety and study data integrity. If you have any questions regarding clinical trial participation, please contact ACADIA by phone in the U.S. at 1-844-422-2342, option 1 or by email medicalinformation@acadia-pharm.com.

We are diligently monitoring and adapting business operations as needed.

ACADIA's response team is monitoring the evolving COVID-19 pandemic globally. We are following the guidance from the U.S. Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO) to ensure we act proactively and quickly support our business operations.

All of us at ACADIA extend our deepest gratitude to the healthcare professionals who are on the front lines of combating the virus, and our thoughts and support go out to all who have been impacted by this public health crisis.



Forward-Looking Statements

Statements included in this document that are not strictly historical in nature are forward-looking statements. These statements include, but are not limited to, statements related to: expectations with respect to ACADIA's business operations and continued ability to manufacture and supply medicines. Actual results may differ materially from those expressed or implied in the forward-looking statements due to various risks and uncertainties, including, among others, unanticipated impacts of COVID-19 on ACADIA's business, including its commercial sales operations, current and planned clinical trials and supply chain. For a discussion of these and other factors, please refer to ACADIA's annual report on Form 10-K for the year ended December 31, 2019 as well as ACADIA's subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and ACADIA undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.